These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 29848096)

  • 1. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
    Anari F; Ramamurthy C; Zibelman M
    Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Microenvironment of Lung Cancer and Therapeutic Implications.
    Mittal V; El Rayes T; Narula N; McGraw TE; Altorki NK; Barcellos-Hoff MH
    Adv Exp Med Biol; 2016; 890():75-110. PubMed ID: 26703800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
    Cui Y; Guo G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward Normalization of the Tumor Microenvironment for Cancer Therapy.
    Zheng J; Gao P
    Integr Cancer Ther; 2019; 18():1534735419862352. PubMed ID: 31282197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tumor microenvironment: part 1.
    Leibovici J; Itzhaki O; Huszar M; Sinai J
    Immunotherapy; 2011 Nov; 3(11):1367-84. PubMed ID: 22053887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.
    Fang H; Declerck YA
    Cancer Res; 2013 Aug; 73(16):4965-77. PubMed ID: 23913938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies.
    Liu Y; Guo J; Huang L
    Theranostics; 2020; 10(7):3099-3117. PubMed ID: 32194857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the tumour microenvironment.
    Laplane L; Duluc D; Bikfalvi A; Larmonier N; Pradeu T
    Int J Cancer; 2019 Nov; 145(10):2611-2618. PubMed ID: 30989643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor microenvironment in ovarian cancer: Premise and promise.
    Jiang Y; Wang C; Zhou S
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188361. PubMed ID: 32234508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal contributions to the carcinogenic process.
    Spaw M; Anant S; Thomas SM
    Mol Carcinog; 2017 Apr; 56(4):1199-1213. PubMed ID: 27787930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the tumor microenvironment by immunotherapy: part 2.
    Leibovici J; Itzhaki O; Huszar M; Sinai J
    Immunotherapy; 2011 Nov; 3(11):1385-408. PubMed ID: 22053888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention.
    El-Nikhely N; Larzabal L; Seeger W; Calvo A; Savai R
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1107-22. PubMed ID: 22667993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the microenvironment in solid tumors.
    Belli C; Trapani D; Viale G; D'Amico P; Duso BA; Della Vigna P; Orsi F; Curigliano G
    Cancer Treat Rev; 2018 Apr; 65():22-32. PubMed ID: 29502037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions that induce modifications in the tumor microenvironment.
    Bernhard EJ
    Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.
    Lu S; Zhang J; Liu D; Li G; Staveley-O'Carroll KF; Li Z; Wu JD
    Clin Cancer Res; 2015 Nov; 21(21):4819-30. PubMed ID: 26106076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune control in hepatocellular carcinoma development and progression: role of stromal cells.
    Sprinzl MF; Galle PR
    Semin Liver Dis; 2014 Nov; 34(4):376-88. PubMed ID: 25369300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.